Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
Warning: file_get_contents(http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=17803883&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 445
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll A multidisciplinary approach to the management of breast cancer, part 2: therapeutic considerations Pruthi S; Boughey JC; Brandt KR; Degnim AC; Dy GK; Goetz MP; Perez EA; Reynolds CA; Schomberg PJ; Ingle JNMayo Clin Proc 2007[Sep]; 82 (9): 1131-40New approaches to breast cancer treatment have enhanced clinical outcomes and patient care. These approaches include advances in breast irradiation and hormonal and systemic adjuvant therapies. In addition to the identification of new drug targets and targeted therapeutics (eg, trastuzumab), there is renewed re-emphasis in the development of biomarkers for the prediction of response to therapy. One example is the pharmacogenetics of tamoxifen metabolism and the individualization of hormonal therapy. The current treatment of breast cancer continues to evolve rapidly, with new scientific and clinical achievements constantly changing the standard of care and leading to substantial reductions in breast cancer mortality. The goal of this article is to provide clinicians who care for women with breast cancer a multidisciplinary, state-of-the art approach to the treatment of these patients.|Antibodies, Monoclonal, Humanized[MESH]|Antibodies, Monoclonal/therapeutic use[MESH]|Antineoplastic Agents, Hormonal/therapeutic use[MESH]|Antineoplastic Agents/pharmacology/therapeutic use[MESH]|Aromatase Inhibitors/therapeutic use[MESH]|Brachytherapy[MESH]|Breast Neoplasms/drug therapy/genetics/radiotherapy/surgery/*therapy[MESH]|Carcinoma, Intraductal, Noninfiltrating/therapy[MESH]|Chemotherapy, Adjuvant[MESH]|Combined Modality Therapy[MESH]|Cytochrome P-450 CYP2D6/genetics[MESH]|Genes, erbB-2/drug effects[MESH]|Humans[MESH]|Lapatinib[MESH]|Male[MESH]|Mastectomy[MESH]|Pharmacogenetics[MESH]|Quinazolines/pharmacology[MESH]|Radiation Dosage[MESH]|Tamoxifen/therapeutic use[MESH]|Trastuzumab[MESH]|Treatment Outcome[MESH] |